The world of mental health support is hitting a major turning point. Thanks to artificial intelligence, taking care of your ...
Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
Zacks Investment Research on MSN
RMD stock set to gain from FDA clearance of AI-enabled smart comfort
Resmed RMD has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback